Medtronic stock reports 13.7 percent Q1 revenue growth

Published on 09/28/2026 at 12:37 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Medtronic stock received a FY27 organic growth outlook of 7.25 percent to 7.75 percent on September 1, 2026. The September 25 close was USD 88.64, within a USD 73.31 to USD 106.33 yearly range.

Reinraumfertigung mit Technikern bei Montage medizintechnischer Präzisionsinstrumente — Medtronic plc (ISIN IE00BTN1Y115) Reinraum-Fertigung zeigt Techniker bei der Montage medizinischer Präzisionsinstrumente sorgfältig, Illustration mit AI erstellt.

Medtronic plc (ISIN IE00BTN1Y115) reported USD 9.756 billion in first-quarter fiscal 2027 revenue, up 13.7 percent from the prior-year quarter. The September 25, 2026 closing price of USD 88.64 on the NYSE gives the stock a market value of USD 113.5 billion.

Guidance rises after Q1 growth

According to Medtronic on September 1, 2026, first-quarter GAAP diluted EPS was USD 1.14, while non-GAAP diluted EPS reached USD 1.45. The company raised FY27 organic revenue growth guidance to 7.25 percent to 7.75 percent from 6.75 percent to 7.25 percent.

The same release showed a wider contribution from the operating portfolio. Cardiovascular revenue increased 19.5 percent to USD 3.927 billion, Neuroscience revenue rose 10.3 percent to USD 2.678 billion, and Medical Surgical revenue advanced 10.0 percent to USD 2.279 billion.

Analysts lift targets, valuation debate remains

Yahoo Finance reported that Mizuho raised its price target from USD 100 to USD 115 and BofA lifted its target from USD 95 to USD 110 after the first-quarter results. Against the September 25 closing price, Mizuho's target stands 29.76 percent above the stock, while BofA's target is 24.11 percent higher.

The targets point to optimism about Medtronic's growth acceleration, but the guidance range remains more measured than the first-quarter result. The company also reported a 53-week fiscal year, making the extra fiscal week a factor in the quarter's 13.7 percent organic growth comparison.

Stock remains below yearly high

Medtronic stock closed at USD 88.64 on the NYSE on September 25, 2026, up USD 0.85, or 0.97 percent, from the prior close of USD 87.79. The session range was USD 87.12 to USD 88.99, while the 52-week range stood at USD 73.31 to USD 106.33.

For investors, the central test is whether the 13.7 percent first-quarter revenue increase can support the 7.25 percent to 7.75 percent full-year organic growth outlook. The next reported quarter will show whether the growth is sustained across Cardiovascular, Neuroscience, Medical Surgical, and Diabetes.